Cite
Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction.
MLA
Ngwenyama, Njabulo, et al. “Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction.” Circulation, vol. 143, no. 12, Mar. 2021, pp. 1242–55. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.120.051889.
APA
Ngwenyama, N., Kirabo, A., Aronovitz, M., Velázquez, F., Carrillo-Salinas, F., Salvador, A. M., Nevers, T., Amarnath, V., Tai, A., Blanton, R. M., Harrison, D. G., & Alcaide, P. (2021). Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction. Circulation, 143(12), 1242–1255. https://doi.org/10.1161/CIRCULATIONAHA.120.051889
Chicago
Ngwenyama, Njabulo, Annet Kirabo, Mark Aronovitz, Francisco Velázquez, Francisco Carrillo-Salinas, Ane M. Salvador, Tania Nevers, et al. 2021. “Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction.” Circulation 143 (12): 1242–55. doi:10.1161/CIRCULATIONAHA.120.051889.